Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients

References

• Van der Heijden YF, Abdullah F, Andrade BB, et al. Building capacity for advances in tuberculosis research; proceedings of the third report international meeting. Tuberculosis (Edinb). 2018;113:153–162. doi:10.1016/j.tube.2018.09.00930514497
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2018, Geneva https://www.who.int/tb/publications/global_report/en/. Accessed 9 18, 2018.
   Google Scholar
• World Health Organization (Producer). Use of high burden country lists for TB by WHO in the post-2015 era, June 2015 meeting of WHO’s Strategic and technical advisory group for TB (STAG-TB). WHO/HTM/TB/2015.29. Geneva: World Health Organization; 2015
   Google Scholar
• Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis Mar. 2012;54(6):784–791.
   PubMed Web of Science ®Google Scholar
• Shah NS, Auld SC, Brust JC, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med. 2017;376(3):243–253.28099825
   PubMed Web of Science ®Google Scholar
• Dowdy DW, Azman AS, Kendall EA, Mathema B. Transforming the fight against tuberculosis: targeting catalysts of transmission. Clin Infect Dis. 2014;59(8):1123–1129.24982034
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis. Geneva: World Health Organization; 2016.
   Google Scholar
• Virenfeldt J, Rudolf F, Camara C, et al. Treatment delay affects clinical severity of tuberculosis: a longitudinal cohort study. BMJ Open. 2014;4(6):e004818.
   PubMed Web of Science ®Google Scholar
• Zumla A, George A, Sharma V, Herbert RH, Oxley A, Oliver M. The WHO 2014 global tuberculosis report–further to go. Lancet Glob Health. 2014;3(1):e10–e12.
   Web of Science ®Google Scholar
• Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005–1015. doi:10.1056/NEJMoa090784720825313
   PubMed Web of Science ®Google Scholar
• Uplekar M, Weil D, Lonnroth K, et al. WHO‘s new end TB strategy. Lancet. 2015;385(9979):1799–1801. doi:10.1016/S0140-6736(15)60570-025814376
   PubMed Web of Science ®Google Scholar
• Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13(4):349–361. doi:10.1016/S1473-3099(13)70008-223531388
   PubMed Web of Science ®Google Scholar
• Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76–84. doi:10.1016/S1473-3099(17)30691-629198911
   PubMed Web of Science ®Google Scholar
• Gupta S, Kakkar V. Recent technological advancements in tuberculosis diagnostics - A review. Biosens Bioelectron. 2018;115:14–29. doi:10.1016/j.bios.2018.05.01729783081
   PubMed Web of Science ®Google Scholar
• UNITAID. Tuberculosis: Diagnostics Technology Landscape. 5th Geneva, Switzerland; 2017.
   Google Scholar
• Wallis RS, Kim P, Cole S, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis. 2013;13(4):362–372. doi:10.1016/S1473-3099(13)70034-323531389
   PubMed Web of Science ®Google Scholar
• Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A. 1984;81(3):908–912.6422465
   PubMed Web of Science ®Google Scholar
• Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5(11):2516–2522.1907934
   PubMed Web of Science ®Google Scholar
• Werner ER, Bitterlich G, Fuchs D, et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci. 1987;41(3):273–280.3110526
   PubMed Web of Science ®Google Scholar
• Carlin JM, Borden EC, Sondel PM, Byrne GI. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol. 1989;45(1):29–34.2463322
   PubMed Web of Science ®Google Scholar
• Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood. 2009;113(11):2394–2401. doi:10.1182/blood-2008-07-14448519023117
   PubMed Web of Science ®Google Scholar
• Gautam US, Foreman TW, Bucsan AN, et al. In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2018;115(1):E62–E71. doi:10.1073/pnas.171137311429255022
   PubMed Web of Science ®Google Scholar
• Seo KJ, Yoo CY, Im SY, et al. A possible complementary tool for diagnosing tuberculosis: a feasibility test of immunohistochemical markers. Int J Clin Exp Pathol. 2015;8(11):13900–13910.26823702
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Suda T, Asada K, et al. Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis. Clin Vaccine Immunol. 2012;19(3):436–442. doi:10.1128/CVI.05402-1122219312
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Miwa S, Akamatsu T, et al. Indoleamine 2,3-dioxygenase in the pathogenesis of tuberculous pleurisy. Int J Tuberc Lung Dis. 2013;17(11):1501–1506. doi:10.5588/ijtld.13.008224125458
   PubMed Web of Science ®Google Scholar
• Van Laarhoven A, Dian S, Aguirre-Gamboa R, et al. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study. Lancet Infect Dis. 2018;18(5):526–535. doi:10.1016/S1473-3099(18)30053-729395996
   PubMed Web of Science ®Google Scholar
• Barry S, Breen R, Lipman M, Johnson M, Janossy G. Impaired antigen-specific CD4(+) T lymphocyte responses in cavitary tuberculosis. Tuberculosis (Edinb). 2009;89(1):48–53. doi:10.1016/j.tube.2008.07.00218799355
   PubMed Web of Science ®Google Scholar
• Tan Q, Xie WP, Min R, et al. Characterization of Th1- and Th2-type immune response in human multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 2012;31(6):1233–1242. doi:10.1007/s10096-011-1434-422042558
   PubMed Web of Science ®Google Scholar
• Tan Q, Min R, Wang H, et al. Modulation of IFN-gamma and IL-17 is critical in human immune responses to multidrug-resistant tuberculosis in Eastern Chinese Han population. Respirology Supplement, 16th Congress of the Asian Pacific Society of Respirology, Shanghai, China, 05 11 2011, APSR-ONL-885,2: 16.
   Google Scholar
• Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: what we don‘t know can, and does, hurt us. Science. 2010;328(5980):852–856. doi:10.1126/science.118478420466922
   PubMed Web of Science ®Google Scholar
• Multidrug-resistant tuberculosis (MDR-TB) indicators. A minimum set of indicators for the programmatic management of MDR-TB in national tuberculosis control programmes. WHO/HTM/TB/2010.11. Geneva: World Health Organization; 2010
   Google Scholar
• Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J. 2015;45(1):150–160. doi:10.1183/09031936.0010181425261327
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Reddy MC, Ioerger TR, et al. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell. 2013;155(6):1296–1308. doi:10.1016/j.cell.2013.10.04524315099
   PubMed Web of Science ®Google Scholar
• Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan‘s metabolites in exercise, inflammation, and mental health. Science. 2017;357(6349):eaaf9794. doi:10.1126/science.aaf979428751584
   PubMed Web of Science ®Google Scholar
• Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol. 2002;168(8):3771–3776.11937528
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by kynurenines. Adv Exp Med Biol. 2003;527:183–190.15206731
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176(11):6752–6761.16709834
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002;297(5588):1867–1870.12228717
   PubMed Web of Science ®Google Scholar
• Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281(5380):1191–1193.9712583
   PubMed Web of Science ®Google Scholar
• Mehra S, Alvarez X, Didier PJ, et al. Granuloma correlates of protection against tuberculosis and mechanisms of immune modulation by Mycobacterium tuberculosis. J Infect Dis. 2013;207(7):1115–1127.23255564
   PubMed Web of Science ®Google Scholar
• Li N, Xie WP, Kong H, et al. Enrichment of regulatory T-cells in blood of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;19(10):1230–1238.26459539
   PubMed Web of Science ®Google Scholar
• Adu-Gyamfi CG, Snyman T, Hoffmann CJ, et al. Plasma indoleamine 2, 3-dioxygenase, a biomarker for tuberculosis in human immunodeficiency virus-infected Patients. Clin Infect Dis. 2017;65(8):1356–1358.29017244
   PubMed Web of Science ®Google Scholar
• Mazzarella G, Bianco A, Perna F, et al. T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis. Clin Exp Immunol. 2003;132(2):283–288.12699418
   PubMed Web of Science ®Google Scholar
• Ong CW, Elkington PT, Friedland JS. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am J Respir Crit Care Med. 2014;190(1):9–18.24713029
   PubMed Web of Science ®Google Scholar
• Cha J, Lee HY, Lee KS, et al. Radiological findings of extensively drug-resistant pulmonary tuberculosis in non-AIDS adults: comparisons with findings of multidrug-resistant and drug-sensitive tuberculosis. Korean J Radiol. 2009;10(3):207–216.19412508
   PubMed Web of Science ®Google Scholar
• Cheon H. Comparison of CT findings of between MDR-TB and XDR-TB: a propensity score matching study. Imaging Med. 2017;9:125–129.
   Google Scholar
• Fishman JE, Sais GJ, Schwartz DS, Otten J. Radiographic findings and patterns in multidrug-resistant tuberculosis. J Thorac Imaging. 1998;13(1):65–71.9440843
   PubMed Web of Science ®Google Scholar
• Kim SH, Min JH, Lee JY. Radiological findings of primary multidrug-resistant pulmonary tuberculosis in HIV-seronegative patients. Hong Kong J Radiol. 2014;17:4–8.
   Google Scholar
• Van Dyck P, Vanhoenacker FM, Van Den Brande P, De Schepper AM. Imaging of pulmonary tuberculosis. Eur Radiol. 2003;13(8):1771–1785.12942281
   PubMed Web of Science ®Google Scholar
• Zhang L, Pang Y, Yu X, et al. Risk factors for pulmonary cavitation in tuberculosis patients from China. Emerg Microbes Infect. 2016;5(10):e110.27729644
   PubMed Web of Science ®Google Scholar
• Platten M, Wick W. Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72(21):5435–5440.23090118
   PubMed Web of Science ®Google Scholar
• Ho JC, Leung CC. Management of co-existent tuberculosis and lung cancer. Lung Cancer. 2018;122:83–87.30032851
   PubMed Web of Science ®Google Scholar
• Qi LP, Chen KN, Zhou XJ, et al. Conventional MRI to detect the differences between mass-like tuberculosis and lung cancer. J Thorac Dis. 2018;10(10):5673–5684.30505475
   PubMed Web of Science ®Google Scholar
• Niyonkuru A, Bakari KH, Lan X. (18)F-fluoro-2-deoxy-d-glucose PET/computed tomography evaluation of lung cancer in populations with high prevalence of tuberculosis and other granulomatous disease. PET Clin. 2018;13(1):19–31.29157383
   PubMed Web of Science ®Google Scholar
• Lang S, Sun J, Wang X, et al. Asymptomatic pulmonary tuberculosis mimicking lung cancer on imaging: a retrospective study. Exp Ther Med. 2017;14(3):2180–2188.28962139
   PubMed Web of Science ®Google Scholar
• Kim YI, Goo JM, Kim HY, Song JW, Im JG. Coexisting bronchogenic carcinoma and pulmonary tuberculosis in the same lobe: radiologic findings and clinical significance. Korean J Radiol. 2001;2(3):138–144.11752984
   PubMed Web of Science ®Google Scholar
• Yu YY, Pinsky PF, Caporaso NE, et al. Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial. Arch Intern Med. 2008;168(21):2326–2332. discussion 2332.19029496
   PubMedGoogle Scholar
• Davies PD, Pai M. The diagnosis and misdiagnosis of tuberculosis. Int J Tuberc Lung Dis. 2008;12(11):1226–1234.18926032
   PubMed Web of Science ®Google Scholar
• Leng S, Zheng J, Jin Y, et al. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis. Clin Chim Acta. 2018;477:160–165.29113814
   PubMed Web of Science ®Google Scholar
• Liu C, Sun B, Xu B, et al. A panel containing PD-1, IL-2Ralpha, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease. Cancer Manag Res. 2018;10:1749–1761.29983594
   PubMed Web of Science ®Google Scholar